Lexicon Pharmaceuticals (LXRX)
Develops medicines for heart failure, cardiometabolic conditions, and neuropathic pain.
Something off on this page? Send us feedback.
Develops medicines centered on sotagliflozin and other candidates for cardiometabolic conditions and pain. Keeps INPEFA available for heart-failure patients and existing prescribers while directing most resources to clinical development.
Develops medicines centered on sotagliflozin for heart failure and other cardiometabolic conditions. INPEFA, the approved form of sotagliflozin, remains available to heart-failure patients and existing prescribers while the company directs most resources to clinical development.
Sotagliflozin is in the pivotal SONATA-HCM trial for hypertrophic cardiomyopathy and is pursued as ZYNQUISTA for type 1 diabetes. Pilavapadin is being advanced for diabetic peripheral neuropathic pain, and LX9851 is licensed to Novo Nordisk for obesity and metabolic disorders.
Following the removal of commercial operations and field promotion in 2024, the business concentrates on clinical development rather than an internal commercial field force. Its operations depend on trial progress, regulatory approvals, collaborations, and commercialization.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Mar 12, 2026 | H.C. Wainwright | Target | $6 | ||
| Mar 4, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $190.6M · Total debt $59.3M · Total assets $250.1M · Shareholders' equity $174.5M
- Revenue
- $692.0K
- Operating income
- −$26.5M
- Net income
- −$31.8M
No dividends on record.
| Institutions155 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 82.33% | 366.31M shares | |
| Insiders17 holders · as of Jun 4, 2026 | 31.37% | 139.58M shares | |
| Strategic holders2 holders · as of Feb 12, 2026 | 37.12% | 165.17M shares | |
| Adds to | 150.82% |
444.96M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 150.82%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Artal Group S.A.Institution | 39.36% | 175.16M | 13Fas of Jun 30, 2026 |
Invus Global Management, LLCStrategicdirector, 10 percent owner | 36.78% | 163.64M | Form 4filed Feb 4, 2026 ↗ |
Participations S.a r.l. Artal1Insiderdirector, 10 percent owner | 30.61% | 136.18M | Form 4filed May 8, 2026 ↗ |
FMR LLCInstitution | 11.64% | 51.78M | 13Fas of Jun 30, 2026 |
Siren, L.L.C.Institution | 9.96% | 44.30M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Participations S.a r.l. Artal reports a block also reported by Artal Group S.A.; it is counted once, under Artal Group S.A.
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 25, 2026 | Raymond Debbane | director | +2,000 | $1.49 |
| Feb 23, 2026 | Raymond Debbane | director | +100,000 | $1.47 |
| Feb 19, 2026 | Raymond Debbane | director | +50,000 | $1.44 |
| Feb 20, 2026 | Raymond Debbane | director | +100,000 | $1.48 |
| Feb 13, 2026 | Raymond Debbane | director | +57,952 | $1.31 |
- AstraZeneca (ADR)
Farxiga is a U.S.-approved SGLT2 therapy for heart failure
- Eli Lilly
Jardiance is a U.S.-approved SGLT2 therapy for heart failure
- Bristol-Myers Squibb
CAMZYOS is an FDA-approved cardiac myosin inhibitor for obstructive HCM
- Cytokinetics
MYQORZO is an FDA-approved cardiac myosin inhibitor for obstructive HCM
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals | $2.25 | 0.00% | $995.0M | — | — | 24.0 | −97.6% |
| AstraZeneca (ADR) | $164.32 | +1.65% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Eli Lilly | $1,165.19 | +0.50% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Cytokinetics | $73.50 | +2.05% | $8.95B | — | — | 126.1 | −57.1% |
| Median | 24.3 | 15.2 | 8.9 | +6.1% |